High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice.

High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice. Antimicrob Agents Chemother. 2018 May 21;: Authors: Norman G, Campeau J, Sim VL Abstract Prion diseases are a group of neurodegenerative diseases associated with the misfolding of the cellular prion protein (PrPC) into the infectious form (PrPSc). There are currently no treatments for prion disease. Bile acids have the ability to protect hepatocytes from apoptosis and are neuroprotective in animal models of other protein folding neurodegenerative diseases including Huntington's, Parkinson's, and Alzheimer's disease. Importantly, bile acids are approved for clinical use in patients with cirrhosis, and have recently been shown to be safe and possibly effective in pilot trials of patients with amyotrophic lateral sclerosis (ALS). We previously reported that the bile acid, ursodeoxycholic acid (UDCA), given early in disease, prolonged incubation periods in male RML-infected mice. Here we expand on this result to include tauro-ursodeoxycholic acid (TUDCA) treatment trials and delayed UDCA treatment. We demonstrate that, despite a high dose of TUDCA given early in disease, there was no significant difference in incubation periods between treated and untreated cohorts, regardless of sex. In addition, delayed treatment with a high dose of UDCA resulted in a significant shortening of the average survival time for both male and female mice when compared to their sex-matched con...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research

Related Links:

Conclusion: The Activa PC IPG demonstrates a significantly reduced battery life of 2.1 years, with a median battery life of 4.5 years in comparison to 6.6 years in the Kinetra IPG. Future technology developments should therefore be focused on improving the battery life of the newer IPG systems.Stereotact Funct Neurosurg
Source: Stereotactic and Functional Neurosurgery - Category: Neurosurgery Source Type: research
Alzheimer's patients older than 65 benefit the most benefit from deep brain stimulation, according to findings from a recent phase II clinical trial.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
ConclusionsOnco-Move is not likely to be cost-effective. Depending on the decision-makers ’ willingness-to-pay, OnTrack could be considered cost-effective in comparison with UC.Trial registration Clinical trial registration number of the Netherlands Trial Register —NTR2159.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
LIVER disease symptoms, caused by excessive alcohol intake, usually only show when the organ has been severely damaged. It ’s important to recognise these signs as repeated damage can lead to alcoholic liver cirrhosis. There are seven symptoms to look out for.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Essel KG, Moore KN Abstract INTRODUCTION: Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP) is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germline or somatic mutation in the breast cancer gene (BRCA). Overall niraparib is well tolerated and its toxicities, primarily hematologic, are manageable especially with recently released initial dose modification guidelines based on weight and baseline platelet count. The role of niraparib as maintenance following front-line platinum-based chemotherapy as well ...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
“As it prepares to turn 70, the NHS is coming towards the worst decade in its existence as far as funding goes,” began the discussion of health and social care. The mover of the motion said that, “services have been repeatedly run down by a government that prefers tax cuts for the wealthy to a well-funded NHS… we now have a permanent winter for our NHS and workloads and stress loads have gone through the roof for many members.” Tracy Holmes, from Sefton local government branch, told delegates about the bad practise in homecare she had witnessed: from visits of just five minutes scheduled...
Source: UNISON Health care news - Category: UK Health Authors: Tags: Article health health care NDC 2018 save care now social care Source Type: news
Authors: Wang F, Cui S, Wang F, Li F, Tang F, Zhang X, Gao Y, Lv H Abstract OBJECTIVE: Determine the optimal scoring system for evaluation of 6-week bleeding-related mortality in liver cirrhosis patients with acute variceal bleeding (AVB). Prediction effects of six scoring systems, AIMS65 score, Glasgow-Blatchford (GBS) score, full Rockall (FRS) score, the model for end-stage liver disease (MELD), the MELD-Na model and the Child-Turcotte-Pugh (CTP) score were analyzed in this study. METHODS: A total of 202 liver cirrhosis patients with AVB were enrolled between 1 January 2014, and 31 December 2014. All subjects...
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Condition:   Triple Negative Breast Cancer Interventions:   Biological: adagloxad simolenin combined with OBI-821;   Biological: Phosphate-buffered saline (PBS) Sponsor:   OBI Pharma, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Liver Disease and Cirrhosis Intervention:   Diagnostic Test: with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies Sponsor:   Chuncheon Sacred Heart Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Interventions:   Biological: VY-AADC02;   Other: Placebo Sponsor:   Voyager Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ALS | Alzheimer's | Bile | Brain | Chemotherapy | Cirrhosis | Huntington's Disease | Microbiology | Neurology | Parkinson's Disease